JP2019535805A - 重合可能量子ドットナノ粒子、並びにそれを用いた治療薬、除去剤及び刺青剤 - Google Patents
重合可能量子ドットナノ粒子、並びにそれを用いた治療薬、除去剤及び刺青剤 Download PDFInfo
- Publication number
- JP2019535805A JP2019535805A JP2019538740A JP2019538740A JP2019535805A JP 2019535805 A JP2019535805 A JP 2019535805A JP 2019538740 A JP2019538740 A JP 2019538740A JP 2019538740 A JP2019538740 A JP 2019538740A JP 2019535805 A JP2019535805 A JP 2019535805A
- Authority
- JP
- Japan
- Prior art keywords
- quantum dot
- ligand
- nanoparticle conjugate
- dot nanoparticle
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0245—Specific shapes or structures not provided for by any of the groups of A61K8/0241
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/025—Semi-permanent tattoos, stencils, e.g. "permanent make-up"
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
- A61K2800/434—Luminescent, Fluorescent; Optical brighteners; Photosensitizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/614—By macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/62—Coated
- A61K2800/622—Coated by organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/81—Preparation or application process involves irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/95—Involves in-situ formation or cross-linking of polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S977/774—Exhibiting three-dimensional carrier confinement, e.g. quantum dots
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
- Y10S977/892—Liquid phase deposition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
- Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
- Y10S977/897—Polymerization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Geometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
DCC:ジシクロヘキシルカルボジイミド
DCM:ジクロロメタン
DIC:ジイソプロピルカルボジイミド
EDC:1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド塩酸塩
HMMM:ヘキサメトキシメチルメラミン
In(MA)3:ミリスチン酸インジウム
QD:量子ドット
sulfo−NHS:N−ヒドロキシスクシンイミドのスルホ誘導体
SMCC:スクシンイミジル4−(N−マレイミドメチル)シクロヘキサン−1−カルボキシレート
(TMS)3P:トリス(トリメチルシリル)ホスフィン
以下の合成工程が、コンジュゲーションに用いられてよい。リンカーが使用されて、ナノ粒子上のカルボキシル官能基と癌特異的結合リガンド上のアミン末端基との間にアミド基が形成されてよい。既知のリンカー、例えば、QDの無機表面上に直接存在するチオール固定基などが使用できる。当業者には知られているであろう標準的なカップリング条件が用いられてよい。適切なカップリング剤としては、例えば、ジシクロヘキシルカルボジイミド(DCC)、ジイソプロピルカルボジイミド(DIC)、及び1−(3−ジメチルアミノプロピル)−3−エチルカルボジイミド塩酸塩(EDC)などのカルボジイミドが挙げられるが、これらに限定されない。ある実施形態では、カップリング剤はEDCである。
標準的なEDC化学を用いて、カルボキシ官能化QDを2−アミノエチルメタクリレート塩酸塩に連結する。得られるドットは、ペンダントメタクリレート基を有しており、標的組織に送達されて、エネルギー源を用いて量子ドットを励起して重合できる。
QD重合可能リガンド結合体は腫瘍細胞によって取り込まれる。外部光源によるQDコンジュゲートの励起は、重合可能リガンドの重合をトリガーして、ドット−ドット架橋を引き起こし、これが組織内凝集と組織壊死又は死をもたらす。図2を参照のこと。
QD重合可能リガンドコンジュゲートは、化粧用刺青にも使用できる。この実施形態では、QD重合可能リガンドコンジュゲートは、所望の組織(例えば、真皮や表皮)に送達される。この実施形態では、重合可能リガンドは、顔料インクを封入する。送達されると、重合可能リガンドナノ粒子から分離して、続いてナノ粒子からの光で照射されることによって励起され、重合がもたらされる。リガンドの重合は、皮膚を通して見える構造をもたらす。
Claims (20)
- ナノ粒子が重合可能リガンドに連結している、量子ドットナノ粒子コンジュゲート。
- 量子ドットナノ粒子が、
コア半導体材料と、
外層と、
を含んでおり、外層は、重合可能リガンドに連結した機能化有機コーティングを含む、請求項1に記載の量子ドットナノ粒子コンジュゲート。 - 重合可能リガンドが、アクリレート、メタクリレート、ジアセチレン、シアノアクリレート、アジド/アルキン対、及びそれらの任意の組合せからなる群から選択される、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 重合可能リガンドがアクリレート及びメタクリレートを含む、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 重合可能リガンドがシアノアクリレートである、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 重合可能リガンドがジアセチレンである、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 重合可能リガンドは、化学的又は物理的作用によって重合する、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 各量子ドットナノ粒子が、II−VI族材料、III−V族材料、I−III−VI族材料、又はそれらの任意の合金若しくはドープされた誘導体を含む、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 量子ドットナノ粒子が、細胞取込促進剤、組織浸透促進剤、又はそれらの組合せを更に含む、請求項1に記載の量子ドットナノ粒子コンジュゲート。
- 細胞死を誘導する方法であって、
i)請求項1に記載の量子ドットナノ粒子コンジュゲートを細胞と接触させる工程と、
ii)化学的又は物理的作用を用いて重合可能リガンドの重合をトリガーする工程と、
を含む方法。 - 細胞死が重合の際に誘導されて、患部組織が視覚化される、請求項10に記載の方法。
- 腫瘍を処置且つ視覚化する方法であって、
i)請求項1に記載の量子ドットナノ粒子コンジュゲートを腫瘍と接触させる工程と、
ii)化学的又は物理的作用を用いて重合可能リガンドの重合をトリガーする工程と、
を含む、方法。 - 不要な組織を除去する方法であって、
i)請求項1に記載の量子ドットナノ粒子コンジュゲートを望ましくない組織と接触させる工程と、
ii)化学的又は物理的作用を用いて重合可能リガンドの重合をトリガーする工程と、
を含む方法。 - 不要な組織は、静脈瘤、毛細血管拡張、及びクモ母斑から選択される、請求項13に記載の方法。
- 重合時に細胞死を誘導するための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
- 重合時に細胞死を誘導し、患部組織を画像化するための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
- 悪性腫瘍と良性腫瘍の可視化及び処置のための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
- 軟部腫瘍と固形腫瘍の可視化及び処置のための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
- 化粧用刺青のための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
- 望ましくない組織、静脈瘤、毛細血管拡張、及びクモ母斑を切除するための請求項1に記載の量子ドットナノ粒子コンジュゲートの使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662403877P | 2016-10-04 | 2016-10-04 | |
US15/718,239 | 2017-09-28 | ||
US15/718,239 US20180092815A1 (en) | 2016-10-04 | 2017-09-28 | Polymerizable quantum dot nanoparticles and their use as therapeutic, ablation and tattooing agents |
PCT/IB2017/055979 WO2018065860A1 (en) | 2016-10-04 | 2017-09-28 | Polymerizable quantum dot nanoparticles and their use as therapeutic, ablation and tattooing agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019535805A true JP2019535805A (ja) | 2019-12-12 |
Family
ID=61756888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019538740A Pending JP2019535805A (ja) | 2016-10-04 | 2017-09-28 | 重合可能量子ドットナノ粒子、並びにそれを用いた治療薬、除去剤及び刺青剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180092815A1 (ja) |
EP (1) | EP3522926A1 (ja) |
JP (1) | JP2019535805A (ja) |
KR (1) | KR20190055149A (ja) |
CN (1) | CN109803683A (ja) |
WO (1) | WO2018065860A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230323142A1 (en) * | 2020-09-18 | 2023-10-12 | Ryan ROEDER | Methacrylated nanoparticles and related method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014175A1 (en) * | 2004-05-17 | 2006-01-19 | Imad Naasani | Functionalized fluorescent nanocrystal detection system |
JP2012517011A (ja) * | 2009-02-05 | 2012-07-26 | ナノコ テクノロジーズ リミテッド | 被包されたナノ粒子 |
JP2013079962A (ja) * | 2005-11-16 | 2013-05-02 | Signalomics Bmbh | 蛍光ナノ粒子 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1436844B1 (en) * | 2001-09-05 | 2016-03-23 | Rensselaer Polytechnic Institute | Passivated nanoparticles, method of fabrication thereof, and devices incorporating nanoparticles |
JP4555055B2 (ja) * | 2004-11-12 | 2010-09-29 | 日立ソフトウエアエンジニアリング株式会社 | 高発光特性を有する半導体ナノ粒子 |
EP2185598A4 (en) * | 2007-08-23 | 2011-02-09 | Agency Science Tech & Res | PARTICLE SURFACE POLYMERIZATION WITH INVERTED MICELLES |
WO2009137053A1 (en) * | 2008-05-06 | 2009-11-12 | Qd Vision, Inc. | Optical components, systems including an optical component, and devices |
US8968705B2 (en) * | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
GB0916699D0 (en) * | 2009-09-23 | 2009-11-04 | Nanoco Technologies Ltd | Semiconductor nanoparticle-based materials |
KR101228106B1 (ko) * | 2010-01-21 | 2013-02-01 | 광주과학기술원 | 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체 |
EP2717920A4 (en) * | 2011-06-11 | 2015-04-29 | Univ Central Florida Res Found | ACTIVATED NANOSOUNDS FOR INTRACELLULAR DRUG DELIVERY |
CN104245568B (zh) * | 2011-12-22 | 2017-10-03 | 纳米技术有限公司 | 表面改性的纳米粒子 |
CN103893128B (zh) * | 2014-04-28 | 2017-07-14 | 中国科学院宁波材料技术与工程研究所 | 一种肿瘤治疗复合纳米材料及其制备 |
-
2017
- 2017-09-28 CN CN201780061021.6A patent/CN109803683A/zh active Pending
- 2017-09-28 EP EP17797723.8A patent/EP3522926A1/en not_active Withdrawn
- 2017-09-28 KR KR1020197010757A patent/KR20190055149A/ko not_active Application Discontinuation
- 2017-09-28 JP JP2019538740A patent/JP2019535805A/ja active Pending
- 2017-09-28 US US15/718,239 patent/US20180092815A1/en not_active Abandoned
- 2017-09-28 WO PCT/IB2017/055979 patent/WO2018065860A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060014175A1 (en) * | 2004-05-17 | 2006-01-19 | Imad Naasani | Functionalized fluorescent nanocrystal detection system |
JP2013079962A (ja) * | 2005-11-16 | 2013-05-02 | Signalomics Bmbh | 蛍光ナノ粒子 |
JP2012517011A (ja) * | 2009-02-05 | 2012-07-26 | ナノコ テクノロジーズ リミテッド | 被包されたナノ粒子 |
Non-Patent Citations (2)
Title |
---|
DOMINIK JANCZEWSKI ET AL, EUROPEAN POLYMER JOURNAL, vol. 45, JPN7020001366, 2009, pages 1912 - 1917, ISSN: 0004518366 * |
JONG-JIN PARK ET AL, NANO LETTERS, vol. 10, JPN6020017347, 2010, pages 2310 - 2317, ISSN: 0004518367 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018065860A1 (en) | 2018-04-12 |
US20180092815A1 (en) | 2018-04-05 |
KR20190055149A (ko) | 2019-05-22 |
EP3522926A1 (en) | 2019-08-14 |
CN109803683A (zh) | 2019-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wagner et al. | Quantum dots in biomedical applications | |
Selvan et al. | Functional and multifunctional nanoparticles for bioimaging and biosensing | |
JP6923956B2 (ja) | エクソソーム−コンジュゲートされた量子ドットナノ粒子、並びにそれを用いたエクソソーム及び癌の検出方法 | |
US9011818B2 (en) | Materials and methods for biological imaging | |
TWI698255B (zh) | 配位體共軛之量子點奈米粒子及使用彼等偵測dna甲基化之方法 | |
US20180011346A1 (en) | Probe for targeting and manipulating mitochondrial function using quantum dots | |
JP2019535805A (ja) | 重合可能量子ドットナノ粒子、並びにそれを用いた治療薬、除去剤及び刺青剤 | |
JP6826105B2 (ja) | 5−アミノレブリン酸がコンジュゲートされた量子ドットナノ粒子 | |
Wang et al. | Optimizing the aqueous phase synthesis of CdTe quantum dots using mixed-ligands system and their applications for imaging of live cancer cells and tumors in vivo | |
US20200306377A1 (en) | Methods for enhancing 5-aminolevulinic acid-based medical imaging and phototherapy | |
KR102011566B1 (ko) | 효율적으로 펩티드 사슬을 절단하는 효소에 감응하는 나노입자 표면 분자체 및 그 제조방법 | |
WO2020120970A1 (en) | Methods for enhancing indocyanine green medical imaging and phototherapy | |
Santra et al. | Quantum dots for cancer imaging | |
Ma et al. | Quantum Dots (QDs) for Tumor Targeting Theranostics | |
Lee et al. | Preparation of near-infrared quantum dots-herceptin conjugates for cancer imaging | |
Wang | Aqueous phase synthesis and functionalization of semiconductor quantum dots for biomedical applications | |
Mansur et al. | Fluorescent Nanohybrids: Cancer Diagnosis and Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200818 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210608 |